# F9

## Overview
The F9 gene encodes coagulation factor IX, a vital serine protease involved in the intrinsic pathway of blood coagulation. This gene is located on the X chromosome and is primarily expressed in the liver, where it undergoes post-translational modifications essential for its function in hemostasis (BoltonMaggs2003Haemophilias). Coagulation factor IX, once activated to factor IXa, plays a crucial role in the coagulation cascade by forming a complex with factor VIIIa, calcium ions, and phospholipids, which subsequently activates factor X, leading to thrombin generation and fibrin clot formation (Monroe2006What). Mutations in the F9 gene can result in hemophilia B, a genetic disorder characterized by impaired blood clotting and prolonged bleeding episodes (Li2014Mutation). The study of F9 and its encoded protein is critical for understanding and treating coagulation disorders, particularly hemophilia B, which varies in severity depending on the specific genetic mutations present (Li2014Mutation; Yu2012Spectrum).

## Structure
The F9 gene encodes coagulation factor IX, a protein crucial for blood clotting. The primary structure of factor IX consists of a 461-amino acid polypeptide, which is processed into a mature 415-amino acid protein after the removal of a 28-amino acid signal peptide and an 18-amino acid propeptide (Callaghan2014Cellular). The secondary structure includes domains such as the γ-carboxyglutamic acid (Gla) domain, epidermal growth factor (EGF)-like domains, and a serine protease catalytic domain (Callaghan2014Cellular).

The tertiary structure of factor IX involves the folding of these domains into a functional conformation, stabilized by disulfide bonds. A critical disulfide bond connects the light and heavy chains of the active enzyme, which are formed after activation by cleavage at specific arginine residues (Callaghan2014Cellular). The quaternary structure is characterized by the formation of a two-chain serine protease, with the light chain containing the Gla, EGF1, and EGF2 domains, and the heavy chain containing the serine protease domain (Callaghan2014Cellular).

Post-translational modifications are essential for factor IX function, including γ-carboxylation of glutamic acid residues, which is crucial for calcium binding, and various glycosylations and phosphorylations (Callaghan2014Cellular). These modifications are vital for the protein's activation and function in the coagulation cascade (Callaghan2014Cellular). Factor IX does not have known splice variant isoforms mentioned in the provided context.

## Function
The F9 gene encodes coagulation factor IX, a serine protease that plays a critical role in the intrinsic pathway of blood coagulation. In healthy human cells, factor IX is synthesized in the liver and requires vitamin K for its activation, which involves gamma carboxylation of glutamic acid residues to form Gla domains essential for its function (BoltonMaggs2003Haemophilias). Once activated, factor IX, in conjunction with factor VIIIa, calcium ions, and phospholipids from platelets, activates factor X on the platelet surface. This activation is a crucial step in the coagulation cascade, leading to the generation of thrombin and the formation of a stable fibrin clot (Monroe2006What; Wei2024A).

Factor IX is not inhibited by the tissue factor pathway inhibitor and is inhibited more slowly by antithrombin compared to factor Xa, allowing it to move from tissue factor-bearing cells to platelets, where it participates in the amplification phase of coagulation (Monroe2006What). The proper function of factor IX is essential for effective hemostasis, as its deficiency or dysfunction can lead to hemophilia B, characterized by insufficient thrombin generation and inadequate clot formation (Nathwani2014LongTerm).

## Clinical Significance
Mutations in the F9 gene, which encodes coagulation factor IX, are primarily associated with hemophilia B, a recessive X-linked bleeding disorder characterized by defective or insufficient factor IX activity. This condition leads to prolonged bleeding episodes due to impaired blood clotting. The severity of hemophilia B varies depending on the type of mutation present in the F9 gene. Severe cases are often linked to frameshift, nonsense, large deletion, and splicing mutations, which can result in undetectable levels of factor IX activity (Li2014Mutation). Missense mutations, which are the most common type, can lead to a range of severities from mild to severe hemophilia B (Li2014Mutation; Yu2012Spectrum).

Inhibitor development, a complication where the immune system attacks factor IX replacement therapy, is more frequently observed in patients with severe hemophilia B, particularly those with nonsense mutations or large deletions (Li2014Mutation). The presence of inhibitors complicates treatment and may require alternative therapeutic strategies (Li2014Mutation).

The F9 gene mutations are distributed across all exons, with a significant concentration in the protease domain, particularly exon 8 (Lu2019The). De novo mutations and somatic mosaicism have also been observed, contributing to the genetic diversity seen in hemophilia B cases (Lu2019The).

## Interactions
Coagulation factor IX (F9) is a key protein in the blood coagulation process, interacting with several other proteins to facilitate clot formation. Factor IX is activated to factor IXa, which then plays a crucial role in the assembly of the factor X-activating complex on activated platelet surfaces. This complex formation involves interactions with the cofactor factor VIIIa and the substrate factor X. Factor IXa binds to thrombin-activated platelets, with its binding affinity enhanced in the presence of factors VIIIa and X, which induce high-affinity binding sites specific to factor IXa (Ahmad1989Comparative).

The second epidermal growth factor (EGF2) domain of factor IXa, particularly residues 88-109, is critical for its binding to platelets and the assembly of the factor X-activating complex. This domain mediates interactions with procoagulant surfaces, enhancing the catalytic efficiency of factor IXa in activating factor X (Wilkinson2002The).

Factor IXa also competes with other coagulation proteins for binding sites on platelets. Factor X can displace bound factor IXa, while other proteins like high molecular weight kininogen and factor XI do not affect its binding, indicating a specific interaction crucial for coagulation (Ahmad1989Comparative).


## References


[1. (Yu2012Spectrum) Tingting Yu, Jing Dai, Hongjing Liu, Qiulan Ding, Yelin Lu, Hongli Wang, Xuefeng Wang, and Qihua Fu. Spectrum of f9 mutations in chinese haemophilia b patients: identification of 20 novel mutations. Pathology, 44(4):342–347, June 2012. URL: http://dx.doi.org/10.1097/pat.0b013e328353443d, doi:10.1097/pat.0b013e328353443d. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/pat.0b013e328353443d)

[2. (Wilkinson2002The) Frank H. Wilkinson, Syed S. Ahmad, and Peter N. Walsh. The factor ixa second epidermal growth factor (egf2) domain mediates platelet binding and assembly of the factor x activating complex. Journal of Biological Chemistry, 277(8):5734–5741, February 2002. URL: http://dx.doi.org/10.1074/jbc.m107753200, doi:10.1074/jbc.m107753200. This article has 30 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m107753200)

[3. (Monroe2006What) Dougald M. Monroe and Maureane Hoffman. What does it take to make the perfect clot? Arteriosclerosis, Thrombosis, and Vascular Biology, 26(1):41–48, January 2006. URL: http://dx.doi.org/10.1161/01.atv.0000193624.28251.83, doi:10.1161/01.atv.0000193624.28251.83. This article has 286 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1161/01.atv.0000193624.28251.83)

[4. (Nathwani2014LongTerm) Amit C. Nathwani, Ulreke M. Reiss, Edward G.D. Tuddenham, Cecilia Rosales, Pratima Chowdary, Jenny McIntosh, Marco Della Peruta, Elsa Lheriteau, Nishal Patel, Deepak Raj, Anne Riddell, Jun Pie, Savita Rangarajan, David Bevan, Michael Recht, Yu-Min Shen, Kathleen G. Halka, Etiena Basner-Tschakarjan, Federico Mingozzi, Katherine A. High, James Allay, Mark A. Kay, Catherine Y.C. Ng, Junfang Zhou, Maria Cancio, Christopher L. Morton, John T. Gray, Deokumar Srivastava, Arthur W. Nienhuis, and Andrew M. Davidoff. Long-term safety and efficacy of factor ix gene therapy in hemophilia b. New England Journal of Medicine, 371(21):1994–2004, November 2014. URL: http://dx.doi.org/10.1056/nejmoa1407309, doi:10.1056/nejmoa1407309. This article has 1036 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1056/nejmoa1407309)

[5. (Ahmad1989Comparative) S S Ahmad, R Rawala-Sheikh, and P N Walsh. Comparative interactions of factor ix and factor ixa with human platelets. Journal of Biological Chemistry, 264(6):3244–3251, February 1989. URL: http://dx.doi.org/10.1016/s0021-9258(18)94058-5, doi:10.1016/s0021-9258(18)94058-5. This article has 78 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)94058-5)

[6. (Callaghan2014Cellular) Michael U. Callaghan and Randal J. Kaufman. Cellular processing of factor viii and factor ix. April 2014. URL: http://dx.doi.org/10.1002/9781118398258.ch2, doi:10.1002/9781118398258.ch2. This article has 0 citations.](https://doi.org/10.1002/9781118398258.ch2)

[7. (Wei2024A) Xuqian Wei, Houliang Zhang, Weibin Chen, Jian Zhang, and Jing Dai. A study of recurrent life-threatening thrombosis accompanied with the duplication of the factor ix gene. Thrombosis Journal, January 2024. URL: http://dx.doi.org/10.1186/s12959-023-00570-8, doi:10.1186/s12959-023-00570-8. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12959-023-00570-8)

[8. (BoltonMaggs2003Haemophilias) Paula HB Bolton-Maggs and K John Pasi. Haemophilias a and b. The Lancet, 361(9371):1801–1809, May 2003. URL: http://dx.doi.org/10.1016/s0140-6736(03)13405-8, doi:10.1016/s0140-6736(03)13405-8. This article has 570 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0140-6736(03)13405-8)

[9. (Lu2019The) Yeling Lu, Xi Wu, Jing Dai, Qiulan Ding, Wenman Wu, and Xuefeng Wang. The characteristics and spectrum of f9 mutations in chinese sporadic haemophilia b pedigrees. Haemophilia, 25(2):316–323, January 2019. URL: http://dx.doi.org/10.1111/hae.13681, doi:10.1111/hae.13681. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/hae.13681)

[10. (Li2014Mutation) Tengguo Li, Connie H. Miller, Jennifer Driggers, Amanda B. Payne, Dorothy Ellingsen, and W. Craig Hooper. Mutation analysis of a cohort of us patients with hemophilia b. American Journal of Hematology, 89(4):375–379, March 2014. URL: http://dx.doi.org/10.1002/ajh.23645, doi:10.1002/ajh.23645. This article has 25 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ajh.23645)